The ingredient aims to deliver a clean taste profile, competitive cost and improved formulation performance across a range of applications Amai Proteins has reached a major regulatory milestone in the…

The ingredient aims to deliver a clean taste profile, competitive cost and improved formulation performance across a range of applications

Amai Proteins has reached a major regulatory milestone in the United States after the U.S. Food and Drug Administration completed its review of the company’s GRAS (Generally Recognised as Safe) notice for sweelin and confirmed it has no safety concerns regarding its use as a general sweetener.

The GRAS notice was submitted just nine months ago, underscoring the strength and quality of the company’s comprehensive safety dossier. With the FDA review now complete, Amai Proteins can accelerate product trials, customer engagement and commercial roll-out across the U.S. food and beverage market.

Sweelin is a next-generation sweet protein designed to enable significant sugar reduction and replace conventional sweeteners with a protein-based alternative. The ingredient aims to deliver a clean taste profile, competitive cost and improved formulation performance across a range of applications.

The regulatory milestone builds on two additional developments for Sweelin:

• First clinical trial on a sweet protein: The company completed what it describes as the world’s first clinical study on a sweet protein, demonstrating that sweelin does not affect blood glucose or insulin levels.
• Clean label positioning: sweelin can be labelled as “Serendipity Berry Sweet Protein”, allowing manufacturers to maintain simple and consumer-friendly ingredient lists without artificial additives, E-numbers or complex chemical names.

Together, these achievements position Sweelin as a high-potential protein-based sweetener aligned with rising demand for sugar reduction, clean label products and GLP-1-friendly food and beverage innovation. The ingredient also taps into the growing protein-focused nutrition trend, offering manufacturers a dual-value proposition in sweetness and functional positioning.

“Receiving FDA GRAS notification for sweelin is a pivotal step for Amai,” said Amir Guttman, CEO of Amai Proteins. “This milestone validates our regulatory strategy and allows us to move forward with commercialisation discussions with partners seeking clean label, next-generation sweetening solutions.”